Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
ParAllele and Affymetrix Partner to Offer New Custom and Standard
Genotyping Products
Affymetrix to Distribute ParAllele Products Under Expanded Relationship
SANTA CLARA, Calif. and SOUTH SAN FRANCISCO, Calif., May 19
/PRNewswire-FirstCall/ -- Affymetrix, Inc. , and ParAllele BioScience today
announced that they have signed a non-exclusive distribution and marketing
agreement. The two companies are now offering early technology access to
ParAllele's MegAllele(TM) genotyping reagents for use with Affymetrix
GeneChip(R) arrays, enabling researchers to perform large-scale genotyping in
their own labs with their own panels of single nucleotide polymorphisms (SNPs).
These SNP genotyping products, which will be formally launched in July, are
ideal for custom genotyping projects. Researchers studying candidate genes or
other regions of the genome have typically genotyped relatively few SNPs per
experiment due to cost and ease-of-use hurdles. Assay design is customized and
comprehensive, enabling researchers to successfully genotype more of the SNPs
they want. These new products offer the ability to genotype up to tens of
thousands of SNPs in a single, flexible assay.
MegAllele(TM) products include genotyping reagent kits and software
specifically designed for use with Affymetrix GeneChip(R) Tag Arrays and
instrumentation systems. The initial offering includes custom panels of 3,000
to 5,000 SNPs and standard panels of up to 10,000 pre-selected SNPs. Over
time, the product portfolio will grow to include additional custom and standard
products. Under the terms of the non-exclusive agreement, which follows a
year-long research and development collaboration, ParAllele will design assays
and manufacture reagent kits and genotyping software. Affymetrix will market
the integrated reagent kits and software together with its arrays and
instrumentation.
"We are enthusiastic to partner with ParAllele to bring their innovative new
genotyping assay to the broad marketplace," said Greg Yap, Sr. Marketing
Director, DNA Analysis for Affymetrix. "The combination of these MegAllele(TM)
brand reagents with our industry-standard GeneChip brand microarrays will give
customers real solutions for candidate gene analysis and custom genotyping,
adding to our growing portfolio of DNA analysis products that range from
whole-genome analysis to resequencing."
"We are delighted to be working with Affymetrix to bring our technology to
customers around the world, leveraging their well established commercial
organization and trusted microarray platform," said Nick Naclerio, President &
CEO of ParAllele BioScience. "This partnership represents an important step in
the execution of our strategy to deliver 'out-of-the-box' ParAllele products to
the genetics research community and complements our full service collaborations
business."
MegAllele(TM) genotyping reagent kits are based on ParAllele's Molecular
Inversion Probe (MIP) technology that allows tens of thousands of genotyping
reactions to be combined in a single tube with unmatched accuracy and
specificity. The results of the assay can be decoded using universal tags
designed by ParAllele. This approach has been successfully proven in the
International Human Haplotype Mapping (HapMap) Project and through ParAllele's
pharmaceutical and academic collaborations. Affymetrix' GeneChip Tag Arrays
contain sets of "tag" sequences that hybridize to complementary sequences
generated in the assay, allowing high-density multiplexing with a simple
readout. Together, these technologies are expected to provide a scalable and
flexible genotyping solution for a wide variety of DNA analysis applications,
including fine mapping and custom SNP genotyping.
About ParAllele BioScience
ParAllele BioScience is accelerating healthcare breakthroughs by providing
comprehensive genetic discovery solutions to the life science research,
pharmaceutical and diagnostic sectors. The company's products and services
utilize a unique approach that leverages novel biochemical processes rather
than complex instrumentation to discover and analyze minute variations in the
human genome. The understanding of how subtle genetic variations contribute to
disease risk, prognosis and drug response will lead to new and more effective
drugs, predictive diagnosis, and the ability to better tailor therapies to
individual patients. To date, ParAllele has established research collaborations
with multiple large pharmaceutical companies and prestigious academic and
government institutions.
Headquartered in South San Francisco, California, ParAllele BioScience was
founded by a team of leading researchers from the Stanford Genome Technology
Center and Uppsala University. The company's investors include Abingworth
Management, Index Ventures, Mohr Davidow Ventures and Versant Ventures. For
more information about ParAllele, please visit the company's website at:
http://www.parallelebio.com/.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve the quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip brand platform, to address growing
markets focused on understanding the relationship between genes and human
health. Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including,
but not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches, manufacturing, product
development, market acceptance (including uncertainties relating to product
development and market acceptance of the Affymetrix and ParAllele
collaboration), personnel retention, uncertainties related to cost and pricing
of Affymetrix products, dependence on collaborative partners, uncertainties
relating to sole source suppliers, uncertainties relating to FDA and other
regulatory approvals, competition, risks relating to intellectual property of
others and the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2003 and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
Affymetrix' expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: ParAllele BioScience
CONTACT: Nick Naclerio, PhD, President & CEO of ParAllele BioSciences,
+1-650-583-5833, or ; or Karen Bergman or Michelle
Corral, both of BCC Partners, +1-650-575-1509 or +1-415-794-8662, for
ParAllele BioScience; or media, Wes Conard, Associate Director, Public
Relations, +1-408-731-5791, or investors, Doug Farrell, Vice President,
Investor Relations, +1-408-731-5285, both of Affymetrix, Inc.
Web site: http://www.paralellebio.com/